0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      HDAC4 mutations cause diabetes and induce β‐cell FoxO1 nuclear exclusion

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Studying patients with rare Mendelian diabetes has uncovered molecular mechanisms regulating β‐cell pathophysiology. Previous studies have shown that Class IIa histone deacetylases (HDAC4, 5, 7, and 9) modulate mammalian pancreatic endocrine cell function and glucose homeostasis.

          Methods

          We performed exome sequencing in one adolescent nonautoimmune diabetic patient and detected one de novo predicted disease‐causing HDAC4 variant (p.His227Arg). We screened our pediatric diabetes cohort with unknown etiology using Sanger sequencing. In mouse pancreatic β‐cell lines (Min6 and SJ cells), we performed insulin secretion assay and quantitative RT‐PCR to measure the β‐cell function transfected with the detected HDAC4 variants and wild type. We carried out immunostaining and Western blot to investigate if the detected HDAC4 variants affect the cellular translocation and acetylation status of Forkhead box protein O1 (FoxO1) in the pancreatic β‐cells.

          Results

          We discovered three HDAC4 mutations (p.His227Arg, p.Asp234Asn, and p.Glu374Lys) in unrelated individuals who had nonautoimmune diabetes with various degrees of β‐cell loss. In mouse pancreatic β‐cell lines, we found that these three HDAC4 mutations decrease insulin secretion, down‐regulate β‐cell‐specific transcriptional factors, and cause nuclear exclusion of acetylated FoxO1.

          Conclusion

          Mutations in HDAC4 disrupt the deacetylation of FoxO1, subsequently decrease the β‐cell function including insulin secretion, resulting in diabetes.

          Related collections

          Most cited references28

          • Record: found
          • Abstract: found
          • Article: not found

          FoxO1 protects against pancreatic beta cell failure through NeuroD and MafA induction.

          Diabetes causes pancreatic beta cell failure through hyperglycemia-induced oxidative stress, or "glucose toxicity." We show that the forkhead protein FoxO1 protects beta cells against oxidative stress by forming a complex with the promyelocytic leukemia protein Pml and the NAD-dependent deacetylase Sirt1 to activate expression of NeuroD and MafA, two Insulin2 (Ins2) gene transcription factors. Using acetylation-defective and acetylation-mimicking mutants, we demonstrate that acetylation targets FoxO1 to Pml and prevents ubiquitin-dependent degradation. We show that hyperglycemia suppresses MafA expression in vivo and that MafA inhibition can be prevented by transgenic expression of constitutively nuclear FoxO1 in beta cells. The findings provide a mechanism linking glucose- and growth factor receptor-activated pathways to protect beta cells against oxidative damage via FoxO proteins.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Acetylation of Foxo1 alters its DNA-binding ability and sensitivity to phosphorylation.

            The FOXO family of forkhead transcription factors plays a key role in a variety of biological processes, including metabolism, cell proliferation, and oxidative stress response. We previously reported that Foxo1, a member of the FOXO family, is regulated through reversible acetylation catalyzed by histone acetyltransferase cAMP-response element-binding protein (CREB)-binding protein (CBP) and NAD-dependent histone deacetylase silent information regulator 2, and that the acetylation at Lys-242, Lys-245, and Lys-262 of Foxo1 attenuates its transcriptional activity. However, the molecular mechanism by which acetylation modulates Foxo1 activity remains unknown. Here, we show that the positive charge of these lysines in Foxo1 contributes to its DNA-binding, and acetylation at these residues by CBP attenuates its ability to bind cognate DNA sequence. Remarkably, we also show that acetylation of Foxo1 increases the levels of its phosphorylation at Ser-253 through the phosphatidylinositol 3-kinase-protein kinase B signaling pathway, and this effect was overridden on the acetylation-deficient Foxo1 mutant. Furthermore, in in vitro kinase reactions, the association of wild-type Foxo1 and its target DNA sequence inhibits the protein kinase B-dependent phosphorylation of Foxo1, whereas mutated Foxo1 proteins, which mimic constitutively acetylated states, are efficiently phosphorylated even in the presence of the DNA. These results suggest that acetylation regulates the function of Foxo1 through altering the affinity with the target DNA and the sensitivity for phosphorylation.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Precision diabetes: learning from monogenic diabetes

              The precision medicine approach of tailoring treatment to the individual characteristics of each patient or subgroup has been a great success in monogenic diabetes subtypes, MODY and neonatal diabetes. This review examines what has led to the success of a precision medicine approach in monogenic diabetes (precision diabetes) and outlines possible implications for type 2 diabetes. For monogenic diabetes, the molecular genetics can define discrete aetiological subtypes that have profound implications on diabetes treatment and can predict future development of associated clinical features, allowing early preventative or supportive treatment. In contrast, type 2 diabetes has overlapping polygenic susceptibility and underlying aetiologies, making it difficult to define discrete clinical subtypes with a dramatic implication for treatment. The implementation of precision medicine in neonatal diabetes was simple and rapid as it was based on single clinical criteria (diagnosed <6 months of age). In contrast, in MODY it was more complex and slow because of the lack of single criteria to identify patients, but it was greatly assisted by the development of a diagnostic probability calculator and associated smartphone app. Experience in monogenic diabetes suggests that successful adoption of a precision diabetes approach in type 2 diabetes will require simple, quick, easily accessible stratification that is based on a combination of routine clinical data, rather than relying on newer technologies. Analysing existing clinical data from routine clinical practice and trials may provide early success for precision medicine in type 2 diabetes. Electronic supplementary material The online version of this article (doi:10.1007/s00125-017-4226-2) contains a slideset of the figures for download, which is available to authorised users.
                Bookmark

                Author and article information

                Contributors
                Maolian@mdc-berlin.de
                Journal
                Mol Genet Genomic Med
                Mol Genet Genomic Med
                10.1002/(ISSN)2324-9269
                MGG3
                Molecular Genetics & Genomic Medicine
                John Wiley and Sons Inc. (Hoboken )
                2324-9269
                09 April 2019
                May 2019
                : 7
                : 5 ( doiID: 10.1002/mgg3.2019.7.issue-5 )
                : e602
                Affiliations
                [ 1 ] Experimental and Clinical Research Center (ECRC) a joint cooperation between the Charité Medical Faculty Max‐Delbrueck‐Center for Molecular Medicine (MDC) Berlin Germany
                [ 2 ] Qingdao Municipal Hospital Qingdao China
                [ 3 ] Max‐Delbrück Center for Molecular Medicine Berlin Germany
                [ 4 ] Department of Pediatrics Anhui Provincial Children’s Hospital Hefei China
                [ 5 ] Division of Pediatric Endocrinology, Department of Pediatrics Hacettepe University Faculty of Medicine Ankara Turkey
                [ 6 ] Institute for Experimental Pediatric Endocrinology Berlin Germany
                [ 7 ] Affiliated Hospital of Guangdong Medical University Zhanjiang China
                [ 8 ] Division of Endocrinology, Department of Paediatric Medicine Sidra Medical & Research Center, OPC Doha Qatar
                [ 9 ] German Center for Cardiovascular Research (DZHK), partner site Greifswald & Department of Internal Medicine B University Medicine Greifswald Greifswald Germany
                [ 10 ] The First Affiliated Hospital of Jinan University Guangzhou China
                [ 11 ] Department of Biology Southern University of Science and Technology Shenzhen China
                [ 12 ] Department of Pediatric Endocrinology and Diabetology Charité Berlin Germany
                Author notes
                [*] [* ] Correspondence

                Maolian Gong, Experimental and Clinical Research Center (ECRC), a joint cooperation between the Charité Medical Faculty and the Max‐Delbrueck‐Center for Molecular Medicine (MDC), Berlin, Germany.

                Email: Maolian@ 123456mdc-berlin.de

                [†]

                These authors contributed equally to this study

                Author information
                https://orcid.org/0000-0001-7384-3429
                Article
                MGG3602
                10.1002/mgg3.602
                6503015
                30968599
                5ac96b18-e98a-4e5a-ae88-9253f5b7d134
                © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 17 October 2018
                : 08 January 2019
                : 09 January 2019
                Page count
                Figures: 3, Tables: 1, Pages: 10, Words: 6672
                Funding
                Funded by: Society for Paediatric Endocrinology (ESPE)
                Award ID: ESPE research unit grant 2012-2014
                Funded by: Das zuckerkranke Kind
                Funded by: European Society for Paediatric Endocrinology
                Award ID: 2012-2014
                Categories
                Original Article
                Original Articles
                Custom metadata
                2.0
                mgg3602
                May 2019
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.6.2.1 mode:remove_FC converted:07.05.2019

                diabetes,foxo1,hdac4 mutations,pancreatic β‐cells
                diabetes, foxo1, hdac4 mutations, pancreatic β‐cells

                Comments

                Comment on this article